The Silent Adherence Killer: Why Health Literacy Is the Pharma Problem Nobody Is Measuring

Right now, there is a patient sitting in a consulting room who has just received a diagnosis, a prescription, and an appointment in three months' time. She nodded in all the right places. She took the package leaflet with her. She said yes when asked whether she had any questions. And she understood almost nothing of what was just explained to her.

She is not an isolated case. She is not uneducated. She belongs to the nearly half of the adult population in Europe who, according to the WHO's European Health Literacy Survey, have inadequate or problematic health literacy, which means that she lacks the ability to find, understand, appraise, and use health information in the way required by the decisions her treatment demands of her. And within a few weeks, there is a high probability that she will be taking her medication incorrectly, if she is still taking it at all.

Over the past ten years, the pharmaceutical industry has invested enormous energy and resources in the adherence problem. It has measured medication possession ratios and proportion of days covered, modeled initial prescription rates, and designed patient support programs around reminder systems and nurse hotlines. What it has largely failed to do is examine the fundamental reason why so many of these measures fall short of their potential. Health literacy is the invisible variable behind virtually every adherence failure, and as long as it is treated as a footnote of public health rather than as a commercial and strategic priority, the adherence problem will remain stubbornly and expensively unsolved.

What health literacy really is and why the statistics are alarming

Health literacy is the ability to access, understand, appraise, and use health information and services in order to make decisions that promote and maintain one's own health. It is not simply a matter of reading ability. A highly educated professional can have excellent general language skills but inadequate health literacy if the clinical concepts relevant to managing their condition are not explained in a way that allows them to meaningfully absorb and act on them.

The scale of the problem in Europe is striking. According to the European Health Literacy Survey, 47.6 percent of the adult population in eight EU member states, namely Germany, Austria, Spain, Ireland, the Netherlands, Poland, Bulgaria, and Greece, had inadequate or problematic health literacy. At the extremes of the spectrum, data from the WHO European Region suggest that limited health literacy affects anywhere from 25 percent of the adult population in countries with stronger health education systems to as much as 72 percent in Germany, where the complexity of the healthcare system significantly amplifies the health literacy challenge.

The WHO is unequivocal in its assessment of the consequences of limited health literacy for health outcomes. It is associated with lower participation in health promotion and disease detection activities, riskier health choices, poorer management of chronic conditions, poor medication adherence, increased hospitalization and rehospitalization, increased morbidity, and premature death. These are not weak associations. They represent a direct causal chain between the ability to understand health information and the ability to act on it correctly and consistently.

The economic burden is just as significant. Limited health literacy causes additional costs estimated at 3 to 5 percent of total annual healthcare expenditure in the WHO European Region. In the US, the figure is estimated at between $106 billion and $238 billion a year in avoidable healthcare costs. And a systematic review published in Cureus in 2025 found that patients with low health literacy had 35 percent more hospital readmissions within 30 days than patients with adequate health literacy, a finding with direct implications for anyone thinking about the real cost of this problem for healthcare systems and the patients who live within them.

The direct link between health literacy and non-adherence

Despite the weight of evidence linking health literacy to health outcomes, only 12 percent of the 387 adherence studies published since 2019 examined health literacy as a primary variable, as the same 2025 systematic review in Cureus shows. Adherence research has largely measured what patients do without sufficiently examining why they do it, and it is precisely this gap in understanding that is the main reason why so many adherence interventions fall short of their potential.

The evidence directly linking health literacy to medication adherence is substantial and growing. The 2025 systematic review in Cureus found that patients with low health literacy had a 2.6 times higher rate of unintentional non-adherence and 68 percent more misinterpretations of prescriptions than patients with adequate health literacy. A study of patients with hypertension published in Scientific Reports in 2025 found a moderate positive correlation between health literacy and medication adherence, confirming that adherence increases significantly as health literacy improves. A meta-analysis of 42 randomized controlled trials with 9,332 participants, published in 2026 in the Journal of Evaluation in Clinical Practice, found that health literacy interventions significantly improved medication adherence, with a standardized mean difference of 0.69, a clinically meaningful effect size.

The mechanism is not complicated once you understand it. Patients who do not fully understand why they are taking a medication are less motivated to take it consistently. Patients who cannot tell whether a side effect is expected, concerning, or dangerous are more likely to stop treatment without informing their doctor. Patients who do not understand that their chronic condition requires ongoing treatment even when they feel well are likely to stop therapy once their symptoms subside. These are not failures of motivation. They are failures of knowledge, and they are preventable.

Why this is a commercial problem and not a purely clinical one

The commercial implications of health literacy have found almost no place in pharmaceutical brand and commercial discussions, and this absence is costing companies money in ways that are currently attributed to other causes.

When a patient discontinues a specialty biologic after six weeks because she is confused about whether her fatigue is a side effect or a sign that the therapy is not working, that discontinuation shows up in the brand data as a persistence failure. When a patient with a chronic condition fills their first prescription but does not pick up a follow-up prescription, it shows up as primary non-adherence. When a patient reduces their dose because they are worried about side effects they cannot make sense of, it shows up as subtherapeutic use. In all three cases, the underlying driver is a health literacy failure, but the commercial reporting system has no mechanism to identify it as such, so the intervention meant to fix it is unlikely to target the right problem.

This matters for the ROI calculation around investments in patient support. A patient support program that sends weekly reminder messages to a patient who stopped taking their medication because they did not understand how it works will achieve zero improvement in adherence, no matter how many messages it sends. A program that identifies the knowledge gap, addresses it with accessible, contextually relevant education at the right point in the treatment journey, and confirms understanding before moving on has a fundamentally different likelihood of changing behavior.

A review of 29 studies that synthesized the relationship between health literacy and healthcare costs, published in Health Services Management Research, found that limited health literacy was an important predictor of inappropriate use of the healthcare system, with people with problematic health literacy showing lower self-efficacy and higher rates of avoidable contact with the healthcare system. For pharmaceutical commercial teams, the translation is direct: patients who understand their therapy stay on it longer, generate more prescription volume, produce better real-world effectiveness data, and are less likely to switch to a competitor after a confusion-driven discontinuation.

Why health literacy is a particularly acute issue in specialty and chronic disease therapies

The health literacy challenge is not evenly distributed across therapeutic areas. It is most acute precisely where the commercial stakes are highest.

Specialty biologics for immunology and oncology, oral therapies for metabolic diseases, and maintenance therapies for cardiovascular and respiratory diseases all share characteristics that amplify the health literacy challenge. They involve complex mechanisms of action that patients need to understand in order to stay motivated. They produce side effect profiles that require contextual interpretation if they are to be managed without discontinuing therapy. They require consistent daily or weekly behavior over long periods during which patients may feel well and question the need for ongoing treatment. And they are frequently prescribed to older patients, patients with multiple comorbidities, and patients in lower socioeconomic groups, precisely those who, according to WHO European data, are disproportionately affected by limited health literacy.

A systematic review published in BMC Public Health in 2025, which examined health literacy and medication adherence specifically in patients from ethnic minorities with type 2 diabetes, found that the relationship between limited health literacy and non-adherence in these populations was further amplified by structural barriers such as language, the cultural framing of illness, and trust in the healthcare system. The conclusion is not that health literacy is irrelevant for the general patient population, but that it is most consequential in the patient groups in which adherence is already hardest to achieve.

Why traditional patient education has failed and what the evidence says about effective alternatives

The pharmaceutical industry's standard response to the patient education challenge has been the package leaflet. It is written by medical writers, reviewed by regulatory affairs teams, validated for linguistic accuracy, and not read by the vast majority of the patients for whom it is intended. Research consistently shows that written materials suited to patients' health literacy need to be pitched at a reading level equivalent to that of a ten- to twelve-year-old child to be accessible to most adult patient populations, and the average pharmaceutical package leaflet is written at a considerably higher level.

The research on what actually improves health literacy, and consequently adherence, clearly points to a different model. A systematic review of digital health interventions and health literacy, published in medRxiv in 2025 and covering 39 studies from 2013 to 2024, found that digital health interventions, including multimedia tools and remote education sessions, consistently improved health literacy across different patient populations when they were designed with accessibility, interactivity, and personalization in mind. Another systematic review of digital health literacy interventions published in PMC found that they typically led to improved health literacy, better medication adherence, and greater self-confidence, particularly in the marginalized communities that bear the highest burden of limited health literacy.

The critical design requirements that consistently emerge from the evidence are not complex, but they are systematically violated by most patient education programs in the pharmaceutical industry. Content must be delivered in plain, accessible language without assuming prior medical knowledge. It must be contextually timed, arriving when it is relevant to what the patient is currently experiencing rather than front-loaded at the time of diagnosis, when information overload is at its peak. It must be interactive rather than passive, enabling patients to ask questions and confirm their understanding instead of simply receiving information. And it must be continuous rather than episodic, because health literacy is not built through a single educational encounter but through repeated, relevant, progressively deeper engagement with information over the course of the treatment journey.

The practical implications for designing patient support programs

Translating the health literacy evidence into the practical design of patient support programs requires three changes in the way most pharmaceutical companies currently think about patient education.

The first change is the shift from providing information to confirming understanding. Most patient support programs are designed to deliver information. The evidence suggests that the problem is not delivering information but confirming that it has been understood in a way that changes behavior. Patient education programs need feedback mechanisms that allow patients to demonstrate their understanding and that flag when a patient's grasp of a key concept, such as why they need to continue treatment when they feel well or how to distinguish an expected side effect from one that requires clinical attention, falls below the threshold required for adherent behavior.

The second change is the shift from generic to personalized education pathways. The health literacy challenge is not uniformly distributed across all patients, and the knowledge gaps that drive non-adherence differ from patient to patient depending on their previous healthcare experience, their specific concerns about the therapy, and the stage of the treatment journey they are at. A patient in the first two weeks of treatment has different educational needs from one who has been on therapy for six months and is beginning to question whether to continue. Patient support platforms that can identify which education gap is relevant to which patient at which point in time, and deliver targeted content accordingly, operate on a fundamentally more effective model than those that deliver the same content to all patients at all times.

The third change is the shift from a one-time educational moment to a continuous learning process. Research on health literacy interventions consistently shows that single encounters produce short-term improvements in knowledge that are not sustained over time. Lasting improvements in health literacy that translate into sustained adherence over a treatment period of twelve or twenty-four months require ongoing educational engagement that reinforces and builds on what was learned earlier. This is exactly what integrated digital health platforms are designed to deliver, and it is one of the strongest arguments for embedding patient education in an engagement ecosystem that patients return to every day, rather than treating it as a one-off exercise during onboarding.

The measurement gap that needs to be closed

For health literacy to be treated as the commercial priority it deserves to be, pharmaceutical commercial teams need to be able to measure it and connect it to outcomes they already care about. Currently, the vast majority of brand teams cannot describe the health literacy profile of their patient population, cannot identify at which point in the treatment journey health literacy failures drive discontinuation, and cannot measure whether their patient support program improves understanding or merely delivers content.

This measurement gap can be closed. Validated short-form health literacy assessment tools exist that can be embedded in digital patient engagement platforms without creating any significant burden for patients. Comprehension tracking, meaning the ability to monitor whether patients engage with educational content and understand key concepts, is a standard feature of well-designed digital health platforms. And the link between specific educational interventions and subsequent adherence behavior, although it requires careful study design to be established causally, is measurable over time in ways that can inform the ongoing optimization of patient support programs.

The companies that start measuring health literacy as a dimension of their patient support programs today are building the diagnostic infrastructure that will enable them to design more effective interventions, justify larger investments in patient support with specific ROI evidence, and differentiate their products in real-world effectiveness data in a way that serves both patients and payers.

Closing the loop

Health literacy is not a public health problem that sits outside the commercial plan. It is a measurable, addressable driver of the adherence gap that simultaneously costs pharmaceutical companies revenue and patients their health outcomes.

The 47.6 percent of European adults with inadequate or problematic health literacy are not failing to take their medication because they do not care about their health. They are failing because the systems designed to support their treatment, from the prescribing consultation to the package leaflet to the support program, were not designed with their actual comprehension needs in mind. This design failure can be corrected, and the evidence on how to correct it is clear, specific, and growing.

Pharmaceutical companies that invest in health literacy-sensitive patient support, that measure understanding rather than just content delivery, that align education with the moments in the treatment journey where it has the greatest impact, and that integrate continuous educational engagement into their patient platform strategies will generate better real-world adherence data, stronger prescriber confidence, and more credible effectiveness evidence than those that continue to equate patient education with patient information.

The gap between what patients know and what they need to know to stay on therapy is one of the most commercially consequential gaps in healthcare. It is also one of the most solvable. The question is simply whether pharmaceutical commercial teams are ready to start measuring it.

Find out how brite helps pharmaceutical companies deliver health literacy-sensitive patient education throughout the entire treatment journey at britehealth.com/en-de/partner/pharma